David Ludwig (Harvard, Boston Childrens Hospital) and journalist Gary Taubes explore the science behind GLP-1s, their impact on insulin, weight loss, and chronic disease, and where dietary strategies like low carb or ketogenic therapy fit in
This is kind of like a lose-lose situation, said Reshma Ramachandran, an assistant professor and health services researcher at Yale University who treats many patients who have turned to compounded GLP-1s because they cant afford the branded drugs
El copago ms bajo, una fraccin del costo de estos medicamentos cuando se pagan de bolsillo, sin duda va a aumentar el acceso para casi 4 millones de beneficiarios que podran cumplir con los requisitos para una receta
The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients